polymers are provided having a structure selected from : r x and r x wherein r x is a polyol moiety and r x is a polyamine moiety , with the x being between 2 and 10 , inclusive , and each r 1 independently has the structure : wherein a divalent amino acid moiety with r 2 being a covalent bond or having from 1 to 8 carbon atoms , and y and z are between 0 and 10 , inclusive , provided that y and z are not both 0 ; is a divalent dicarboxylic acid moiety in which r 3 is an alkylene or cyclolkylene group containing from 1 to about 15 carbon atoms substituted with a total of from 1 to about 10 hydroxyl groups , with at least a portion of the hydroxyl groups being acylated with 3 to 24 carbon atom carboxylic acids ; and r 4 is a poly having the structure : r 5 — a — r 6 — q — with r 5 selected from 1 to 40 carbon atom alkyl groups , — oh —, — or 7 , — nh —, — nhr 7 , — nr 7 r 8 , — c — oh , — c — or 7 , — c — o — c — r 7 , — c - nh 2 , — c — nhr 7 and — c — nhr 7 r 8 ; r 6 , r 7 and r 8 are independently selected from 2 to 40 carbon atom , straight - chain or branched alkylene groups ; q is a divalent linkage moiety ; and a is between 2 and 110 , inclusive . polymer encapsulates of hydrophobic molecules are also disclosed , including pharmaceutical dosage forms containing the encapsulates in which the hydrophobic molecule has biological or pharmaceutical activity , as well as transdermal delivery devices . methods of treating patients with the pharmaceutical dosage forms are also disclosed .